Sammy,
Aside from Sarepta's sketchy FDA approval - without real efficacy data - one other big criticism about Exondys51 is it only treats 13% of boys.
Even with Gene Therapy, we see both Pfizer and Sarepta exclude boys with certain mutations from their program.
Taking the emotion away - looking from the outside - one can see why Sarepta might want to partner with ANP.
...access to 100% of DMD population - USA only - also secure ATL1102 for LGMD too.
$250m per indication + equity position.
Makes perfect sense.
.
Older data but interesting ..MS summary, page-25
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.003(3.90%) |
Mkt cap ! $72.12M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.3¢ | 7.9¢ | $147.1K | 1.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 106165 | 2 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.003 ( 3.90 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.3¢ | 7.9¢ | 108394 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| PER (ASX) Chart |